April 15, 2016 6:14pm
Reflecting the push and pull between the oversold and overbought
Do you care what happened today, you should because it has implications to Monday's sector activity?
Subscribe: http://www.regmedinvestors.com/create-account
Pre-open indication analysis – 2 hit and 2 misses
There is one thing that everyone needs, and that's interpretation and translation of intelligence, not just news or information - we get too much!
- To that end, I report a matrix of variables designed for investor’s consideration concerning the stem, cell and gene therapy regenerative medicine portfolio to track and monitor its pricing metric;
The takeaway is that investor need to decide what actions to take, or not take, based on their specific situation.
U.S. stocks closed lower on Friday; the Dow closed about 29 points lower on the day but gained 1.82% for the week, its best since the week ended March 18. The NASDAQ closed down 0.16% with the index gaining +1.8% for the week,
The NASDAQ closed DOWN -7.67 or -0.16% to 4,938.22 and the DOW closed DOWN -28.97 or -0.16% to 17,897.46.
A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector – the advance/decline line scenario of our 43 covered companies.
- Friday, the stem, cell and gene therapy and regenerative medicine sector opened negative with an A/DL of 13/26 and 4 flats;
- The mid-day stayed negative with an A/DL of 19/21 with 3 flats;
- The closing bell rang barely negative with A/DL of 19/20 with 4 flats
Henry’omics:
After a negative open and staying negative at the mid-day, the sector closed … guess what - negative.
- Yet, the iShares Nasdaq Biotechnology ETF (IBB) rose nearly 1.2%.
The major averages closed off session lows but remained under pressure, after earlier attempting slight gains.
- Why do I feel there was some run-up for days before … Friday marked options expiration?
My pet peeve:
- High-frequency trading accounted for 49 percent of April's daily trading volume of about 6.99 billion shares.
Friday’s handicapping the sector pre-open indications – 2 hit and 2 misses
- Juno Therapeutics (JUNO) closed UP +$0.98 – miss;
- Northwest Bio (NWBO) closed UP +$0.07 – hit;
- Organovo (ONVO) closed DOWN -$0.18 – miss;
- Osiris (OSIR) closed DOWN -$0.17 – hit;
Review my fear gauge or the CBOE Volatility Index (VIX):
- Friday traded below 14;
- Thursday below 14;
- Wednesday traded below 14;
- Tuesday traded near 15;
- Monday traded above 16;
- Last, Friday traded near 15.4 – down!
Who was leading the declines – to of the bottom 5?
- Organovo (ONVO) closed down -$0.18 to $2.73;
- Osiris (OSIR) -$0.17 to $6.40;
- Sangamo (SGMO) -$0.13 to $6.91;
- Asterias (NYSEMKT: AST) -$0.10 to $4.20;
- Vericel (VCEL) closed down -$0.08 to $3.42
Who was UP – top 5:
- Juno (JUNO) closed up +40.98 to $44.31;
- Spark Therapeutics (ONCE) +$0.70 to $35.73;
- Aduro Biotech (ADRO) +$0.55 to $13.745;
- bluebird bio (BLUE) +$0.46 to $50.38;
- Applied Genetic Technologies (AGTC) closed up $0.35 to $17.07
Most active sector stocks + and -:
- Organovo (ONVO) -6.19%;
- Neuralstem (CUR) -3.34%;
- Biostage (BSTG) -3.23%;
Versus …
- Cytori (CYTX) +11.90%;
- Opexa (OPXA) +5.31%
- Brainstorm (BCLI) +5.24%;
Who was FLAT?
- International Stem Cell (ISTO) at $4.00;
- ReNeuron (RENE.L) at $3.125;
- VistaGen (VSTA) at $8.00;
- Verastem (VSTM) at $1.51;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
